Professional Media briefs—March 2012

Share this article:

Jobson Medical Information Holdings filed for Chapter 11 bankruptcy in New York. Jobson's titles include US Pharmacist, 20/20 and Review of Optometry. JMIH also controls accredited CME provider Postgraduate Institute for Medicine and information services /alert Marketing and Frames Data.

Patricia Spinner is now VP sales and marketing for Monthly Prescribing Reference, published by MM&M's parent company Haymarket Media. Spinner was previously group publisher with UBM Canon.

A survey by DTW Research Marketing Group showed that 80% of polled physicians were using e-prescriptions. GPs outpaced specialists with a 75% uptake rate, compared to 66%. Rheumatologists, pulmonary disease specialists and cardiologists were the highest users, in the 90% or higher range.

Media planning and buying firm Communications Media Inc./Compas has realigned its executive team. The company says the change will help to leverage its data and audience information. CEO Stan Woodland's (pictured above) team will include Managing Partner Ken Jones, COO James Woodland, Chief Marketing Officer Dr. Susan Dorfman and CFO John Donovan.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?